NASDAQ:CNSP

Cns Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CNSP

*Your capital is at risk

$5.24

+0.320 (+6.50%)

At Close: Jun 03, 2026

CNS Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 3.68M and sold 0 CNSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	3.68M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 01, 2024 Buy	Common stock P-Purchase	Gumulka Jerzy Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Gumulka Jerzy Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Gumulka Jerzy Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Gumulka Jerzy Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Common stock P-Purchase	Gumulka Jerzy Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Evans Carl Anthony Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Evans Carl Anthony Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Common stock P-Purchase	Evans Carl Anthony Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Common stock P-Purchase	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Common stock P-Purchase	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Common Stock J-Other	Mahery Amy	Director	0 Value: $0
Feb 01, 2024 Buy	Common Stock J-Other	Mahery Amy	Director	0 Value: $0
Feb 01, 2024 Buy	Common stock P-Purchase	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Climaco John M Chief Executive Officer	CEO / President	166 666 Value: $50.0K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Common stock P-Purchase	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Downs Christopher Chief Financial Officer	C-Suite Officer	66 666 Value: $20.0K
Feb 01, 2024 Buy	Common stock P-Purchase	Evans Carl Anthony Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series A Warrant to purchase common stock A-Award	Evans Carl Anthony Director	Director	33 333 Value: $10K
Feb 01, 2024 Buy	Series B Warrant to purchase common stock A-Award	Evans Carl Anthony Director	Director	33 333 Value: $10K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CNS PHARMACEUTICALS, INC.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...

Read Full Profile Here